42 results about "Binding peptide" patented technology

Disclosed herein, are peptides that bind urokinase-type plasminogen activator receptors. The peptides may comprise amino acid sequences of IPPWEAPK (SEQ ID NO: 1), DLAQCQTPTQAAPPTPVSPR (SEQ ID NO: 2), or LHVPLMPAQPAPPK (SEQ ID NO: 3), or retro-inverso amino acid sequences of the above enumerated sequences. Also described herein, are methods of administering compounds comprising peptides that bind urokinase-type plasminogen activator receptors to subjects for the treatment of ovarian cancer and improving wound closure.

The present invention provides novel antigen-binding peptides, such as antibodies or antibody fragments, that specifically bind to selective FXIa inhibitors and / or dual inhibitors of FXIa and plasma kallikrein.The present invention further relates to a method of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharma- ceutical effective amount of the antigen-binding peptides disclosed herein.In addition, the present invention provides detection reagents and methods for detecting FXIa inhibitor levels in biological samples. TIFF2024505390000129.tif113125

A system for binding peptide search for immunotherapy is presented. The system includes employing a deep neural network to predict a peptide presentation given Major Histocompatibility Complex allele sequences and peptide sequences, training a Variational Autoencoder (VAE) to reconstruct peptides by converting the peptide sequences into continuous embedding vectors, running a Monte Carlo Tree Search to generate a first set of positive peptide vaccine candidates, running a Bayesian Optimization search with the trained VAE and a Backpropagation search with the trained VAE to generate a second set of positive peptide vaccine candidates, using a sampling from a Position Weight Matrix (sPWM) to generate a third set of positive peptide vaccine candidates, screening and merging the first, second, and third sets of positive peptide vaccine candidates, and outputting qualified peptides for immunotherapy from the screened and merged sets of positive peptide vaccine candidates to support downstream clinical decision making.

This invention provides a LYTACA polypeptide complex (sRD-Lytaca) targeting the degradation of soluble IL-17RD (sIL-17RD), its preparation method, and its applications. This polypeptide complex is formed by the self-assembly of the sIL-17RD-binding peptide sRDL and the scavenger receptor-binding peptide SRAL after Nap-FF modification and mixing. sRDL can be conjugated with fluorescently labeled molecules to prepare detection reagents for the detection of sIL-17RD. This invention also provides a variant with at least 80% sequence identity with sRDL and retaining binding ability, and pharmaceutical compositions containing sRDL and / or sRD-Lytaca. This invention provides a new technical means for the prevention and treatment of osteoarthritis and diseases related to sIL-17RD protein (such as rheumatoid arthritis).

Provided is a use of a recombinant fusion protein in the preparation of a drug for treating an autoimmune disease that can benefit from the reduction or elimination of CD20+B cells (for example, CD20+ B cell depletion therapy). The recombinant fusion protein comprises i) a CD47-binding peptide, and ii) an anti-CD20 antibody or an antigen-binding portion thereof, wherein the CD47-binding peptide comprises a first extracellular Ig-like domain (SIRPαD1) of signal regulatory protein α (SIRPα), and the anti-CD20 antibody or the antigen-binding portion thereof comprises a heavy chain variable region, a heavy chain constant region, a light chain variable region, and a light chain constant region. The heavy chain variable region comprises VH-CDR1, VH-CDR2, and VH-CDR3, and the light chain variable region comprises VL-CDR1, VL-CDR2, and VL-CDR3, wherein the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 respectively comprise amino acid sequences as shown in GYTFTSYN (SEQ ID NO: 1), IYPGNGDT (SEQ ID NO: 2), ARSTYYGGDWYFNV (SEQ ID NO: 3), SSVSY (SEQ ID NO: 4), ATS, and QQWTSNPPT (SEQ ID NO: 5). The heavy chain constant region has the binding capacity for an FcR or a complement system protein. The CD47-binding peptide is linked to the N-terminus of the heavy chain variable region or light chain variable region of the anti-CD20 antibody or the antigen-binding portion thereof.

The present disclosure provides a heterodimeric antibody, or antigen-binding fragment thereof, comprising two heavy chains with different amino acid sequences and a binding polypeptide. The heterodimer antibody, or the antigen-binding fragment thereof, include a first heavy chain comprising none or one or more modifications and the second heavy chain comprises one or more modifications and is fused to a binding polypeptide, which can form a isopeptide bond with a binding peptide. The present disclosure further provides systems and methods for purifying such heterodimeric antibodies, and antigen-binding fragments thereof.

This article describes multispecific antigen-binding peptides comprising at least three antigen-binding moieties, each of which pairs with a universal light chain peptide. This article also describes multispecific antigen-binding peptides comprising a first antigen-binding moieties and a second antigen-binding moieties, wherein the C-terminus of the CH1 region of the first antigen-binding moieties is coupled to the N-terminus of the heavy chain variable region of the second antigen-binding moieties.

Disclosed herein are anti-KRAS antibodies comprising a PIGR-binding peptide and methods of using the disclosed anti-KRAS antibodies to treat cancer.

This invention provides an antibody fusion protein comprising a binding construct that targets and is capable of binding to Ang-2, IL-6 receptors, and at least one VEGF family member; or an antigen-binding fragment or domain of the antibody fusion protein. The antibody fusion protein comprises an antibody or binding peptide against Ang-2, an antibody against IL-6R, and multiple extracellular domains of the VEGF receptor as binding components. The antibody fusion protein is suitable for treating or controlling ocular or systemic diseases, symptoms, or conditions caused by abnormal angiogenesis, increased vascular leakage, or inflammation.

This description provides peptide compounds that inhibit the human cytokine IL-17. This description also provides pharmaceutical compositions that include these peptide compounds. Furthermore, this description also provides methods of using the peptide compounds, such as methods for treating or preventing diseases, conditions, or disorders mediated by or associated with IL-17.

The present invention relates to a peptide structure specifically binding to carbonic anhydrase IX (CAIX), and a use thereof. The CAIX-binding peptide ligand of the present invention contains D-amino acids, and thus has high binding specificity to CAIX while being stable in the body, and a cyclic CAIX-binding peptide structure comprising same can bind to CAIX with high affinity in the body, and thus is effective in the diagnosis, prevention, suppression or treatment of diseases mediated by CAIX.

A delta-like ligand 3 (DLL3) binding peptide with binding specificity to human DLL3, comprising an amino acid sequence having at least 98%, 95%, or 92% sequence identity with SEQ ID NO: 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 37, 38, 39, 40, 41, 42, 43, 44, 45, or 46.

In a first aspect of the present disclosure, there is provided a computer-implemented method of predicting a binding affinity of a query binder molecule to a query target molecule, the query binder molecule having a first amino acid sequence and the query target molecule having a second amino acid sequence, the method comprising: computing, with the at least one processor, the binding affinity for the query binder molecule to the query target molecule as a weighted combination of reference binding values of reference binder-target subsequence pairs, wherein weights of the weighted combination are based on similarity scores.

The application discloses a light-responsive nucleic acid aptamer, a light-activated DNA polymerase, a kit, a method for preparing the light-activated DNA polymerase, a method for activating the light-activated DNA polymerase, and application of the light-activated DNA polymerase. The light-responsive nucleic acid aptamer comprises an aptamer nucleotide sequence and a photo-cleavable group modified in the aptamer nucleotide sequence, the photo-cleavable group is used for being broken after ultraviolet light irradiation to break the aptamer nucleotide sequence into two nucleotide sequences; the aptamer nucleotide sequence comprises a G-quadruplex nucleotide sequence capable of forming a G-quadruplex and a side nucleotide sequence capable of forming a hairpin structure, the G-quadruplex nucleotide sequence is used for being combined with a G-quadruplex binding peptide fused on a DNA polymerase, and the side nucleotide sequence is used for being combined with an active site of the DNA polymerase. By using the light-activated DNA polymerase provided in the application, the difference in amplification time between samples is reduced, non-specific amplification is avoided, and the accuracy of nucleic acid detection is improved.

The present invention relates to a composition comprising fibroblast activation protein alpha (FAP)-targeting conjugate comprising Formula (I): Y-L-X, wherein Y is a chelator or cytotoxic drug, L is a linker, and X comprises a binding peptide sequence of AA1-AA2-AA3-AA4-AA5-AA6-AA7 which may be in the form of a cyclic peptide, wherein the composition further contains a radioprotectant and / or is in a lyophilized form.

The application belongs to the technical field of medicine, and particularly relates to a modularly constructed targeted-tumor-killing polypeptide-drug conjugate as well as a preparation method and application. The conjugate has a dendritic six-branch scaffold structure, and the scaffold can realize replaceable combination of a targeting polypeptide and a chemotherapeutic drug through chemical modification, so that precise drug delivery can be realized for different tumor types. Among them, a blood vessel binding peptide and an albumin binding peptide are selected as model polypeptides, and a common clinical drug doxorubicin is selected as a model drug. The polypeptide-drug conjugate has high drug loading and stability, can improve the pharmacokinetic characteristics of poorly soluble drugs, prolong in-vivo circulation, has small molecular weight and strong tissue permeability, can be precisely enriched in tumors, has good structural adjustability and functional expansion potential, and exhibits significant anti-tumor effect and safety.

The present application relates to platelet binding peptides and their conjugates, as well as particles comprising these and other peptides and conjugates. In addition, compositions and methods for using these peptides and particles are provided.

This invention relates to the field of biomimetic nanozymes and their preparation technology, disclosing a biomimetic nanozyme, its preparation method, and its applications. A peptide-functionalized biomimetic nanozyme (HRPL) is obtained by loading rapamycin onto HMPB nanozymes, coating the surface with a platelet membrane, and functionalizing it with the integrin-binding peptide LXW7. The binding of the platelet membrane to the LXW7 peptide enables targeted delivery to the site of endothelial injury, promoting endothelial repair and re-epithelialization. In an acidic inflammatory microenvironment, HRPL releases rapamycin, inhibiting smooth muscle cell proliferation and migration, and preventing restenosis. HRPL also scavenges reactive oxygen species, reducing oxidative stress and local inflammation, thereby improving the vascular microenvironment. The therapeutic effect was evaluated using a typical rat carotid balloon injury model. This dual-targeting mechanism not only promotes endothelial repair but also reduces restenosis and inflammation, showing significant clinical therapeutic potential. Especially after stent implantation, HRPL helps improve prognosis, reduce complications, and restore vascular homeostasis.

The invention relates to a binding peptide having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 28 and its use thereof.

The receptor for advanced glycation end-products (RAGE) is a multi-ligand receptor member of the immunoglobulin super family which is able to bind Aβ peptide and 3-sheet fibrils. It is expressed in endothelial cells, smooth muscle cells, microglia and neurons, and is implicated in the transport of Aβ through the blood-brain barrier (BBB), oxidative stress-mediated neurotoxicity, and adverse microglia inflammatory responses. The interaction between RAGE and its ligands is thought to result in pro-inflammatory gene activation. Enhanced levels of RAGE ligands in Alzheimer's disease are thought to contribute to the cause of this disorder. Embodiments of the invention use the RAGE multi-ligand site as an anchoring loci for a conversion electron emitting compound rather than as a receptor to intrinsically activate or block inflammation through the RAGE intracellular cascade through activation of the RAGE cytoplasmic tail (ctRAGE) and mammalian diaphanous 1 (DIAPH1).

Provided herein are fusion polypeptides in which a small polypeptide is modified by fusion with N- and C-termini sequences that interact with one another when in proximity. In some embodiments, the small polypeptide is a cysteine motif binding peptide or a cytokine. Also provided herein are cysteine motif binding peptides, such as from the knob region of an ultralong CDR3, and methods of producing and using the same. Also provided herein are compositions comprising the binding peptides.

The present disclosure provides a heterodimeric antibody, or antigen-binding fragment thereof, comprising two heavy chains with different amino acid sequences and a binding polypeptide. The heterodimer antibody, or the antigen-binding fragment thereof, include a first heavy chain comprising none or one or more modifications and the second heavy chain comprises one or more modifications and is fused to a binding polypeptide, which can form a isopeptide bond with a binding peptide. The present disclosure further provides systems and methods for purifying such heterodimeric antibodies, and antigen-binding fragments thereof.

This invention provides a phage gel sphere, its preparation method, and its application. The phage gel sphere is based on M13K07@SaBP functionalized phage, displaying a streptavidin-binding peptide (SaBP) at the N-terminus of the M13K07 phage P8 protein, and is combined with the virulent phage T7 to enhance its antibacterial activity; sodium alginate, carboxymethyl cellulose, and Ca... 2+ A physical cross-linked main network is formed, and a specific bioaffinity secondary cross-linked network is formed between streptavidin (SA) and M13K07@SaBP, constituting a double-network structure gel sphere. This invention significantly improves the gel cross-linking density, mechanical strength, structural uniformity, and storage stability through SA-SaBP bioaffinity, achieving efficient phage encapsulation and controlled-release, exhibiting specific, efficient, and sustained inhibitory effects against Escherichia coli; it can be widely applied to the precise control of Escherichia coli in various food matrices.

This application discloses a multispecific fusion protein comprising a binding construct that targets and is capable of binding to at least one of DLL4 and VEGF family members; or an antigen-binding fragment or domain thereof. This application also discloses a multispecific fusion protein comprising an antibody against DLL4 or an antigen-binding fragment thereof, multiple extracellular domains of the VEGF receptor or an antibody against at least one VEGF family member or an antigen-binding fragment thereof, and an antibody or binding peptide against Ang-2. The multispecific fusion protein can be used to treat or control ocular or systemic diseases, conditions, or disorders caused by abnormal angiogenesis, increased vascular leakage, inflammation, fibrosis, or combinations thereof.

This invention provides an amphiphilic enzyme-sensitive polymer, its preparation method, and its applications. The amphiphilic enzyme-sensitive polymer is a neutrophil elastase-binding peptide-polyethylene glycol-matrix metalloproteinase 2-responsive peptide-polylactic acid block copolymer. This invention prepares Mal-PEG-GPLGIAGQ through a substitution reaction, then prepares Mal-PEG-GPLGIAGQ-PLA through an amidation reaction, and finally prepares NE-PEG-GPLGIAGQ-PLA through a Michael addition reaction. When this polymer is applied to prepare a nanomicelle drug system, it can self-assemble into structurally stable nanomicelles in aqueous solution and possesses targeting functionality. The prepared nanomicelle drug system exhibits excellent enzyme responsiveness, and after drug loading, it can achieve efficient and safe therapeutic effects.

The application discloses a pathogenic Vibrio Pir B virulence protein binding peptide P2 and application thereof. The small-molecule binding peptide P2 has high affinity with the Pir B virulence protein and has an amino acid sequence of LGSPLLTYGRPQ. The application screens the binding peptide with high affinity with the pathogenic Vibrio Pir B virulence protein from a random peptide library through phage display technology, and the binding peptide is chemically synthesized. After injection of the binding peptide, the survival rate of shrimps after infection with Vibrio can be effectively improved, and the shrimps have a remarkable protection effect in shrimp culture. The binding peptide can efficiently bind to the pathogenic Vibrio Pir B virulence protein, and effectively reduce the virulence of the Pir B protein. In addition, the method can effectively reduce the use of antibiotics in healthy shrimp culture, reduce the generation of drug-resistant strains, and has a good application prospect in the prevention and treatment of shrimp AHPND.

The present application provides an immune inducer comprising a polynucleotide-peptide conjugate or a pharmaceutically acceptable salt thereof as an effective ingredient, the polynucleotide-peptide conjugate consisting of a single-stranded polynucleotide or polynucleotide derivative containing a CpG motif, a peptide, and a spacer covalently bonded at one end to the polynucleotide or polynucleotide derivative and covalently bonded at the other end to the peptide, the peptide being a peptide in which one or more consecutive amino acids at the N-terminus of an MHC-binding peptide are replaced with an amino acid having a reactive functional group for forming a covalent bond with the spacer, wherein the one or more consecutive amino acids do not include anchor residues for binding to MHC.